Compare BridgeBio Pharma Inc (BBIO) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Firy Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B), while Firy Inc. trades at $10.21 (market cap $159.51M). The key difference: BridgeBio Pharma Inc is far larger — about 102.6× Firy Inc.'s market cap. Which is the better fit depends on your goals.
| BBIO | FIRY | |
|---|---|---|
Market Cap | $16.36B | $159.51M |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $12.45 |
52-Week Low | $47.29 | $2.28 |
Enterprise Value | $18.14B | $103.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
FIRY trades at $10.48, up 0.29% today, with a bullish technical outlook from moving averages. The company shows improving revenue trends ($104.5M in 2025) but continues to report significant losses (-$70.41M net income). Recent developments include a $719 million legal victory and corporate rebranding from Skillz Inc. Analyst sentiment remains mixed with a 60% hold rating.
The stock presents speculative potential from legal wins and revenue stabilization, but persistent negative margins and cash burn (-$86.41M net cash flow) pose substantial risks. Upside depends on achieving profitability, while downside risk remains elevated from ongoing operational losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
